S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
China's 1st domestically made passenger plane completes maiden commercial flight
Sell every Stock except ONE (Ad)
In Nigeria’s hard-hit north, families seek justice as armed groups seek control
Biden and McCarthy reach a final deal to avoid US default and now must sell it to Congress
Free A.I. Trade Alerts. Up to 15 opportunities a day. (Ad)
EgyptAir flight from Cairo blows tire during landing in Saudi Arabia
Russia launched 'largest drone attack' on Ukrainian capital before Kyiv Day; 1 killed
3 Free Stock Picks per Day (Ad)
'Succession' fans brace for series finale of Emmy-winning hit drama
Turkey's Erdogan wins another term as president, extends rule into 3rd decade
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
China's 1st domestically made passenger plane completes maiden commercial flight
Sell every Stock except ONE (Ad)
In Nigeria’s hard-hit north, families seek justice as armed groups seek control
Biden and McCarthy reach a final deal to avoid US default and now must sell it to Congress
Free A.I. Trade Alerts. Up to 15 opportunities a day. (Ad)
EgyptAir flight from Cairo blows tire during landing in Saudi Arabia
Russia launched 'largest drone attack' on Ukrainian capital before Kyiv Day; 1 killed
3 Free Stock Picks per Day (Ad)
'Succession' fans brace for series finale of Emmy-winning hit drama
Turkey's Erdogan wins another term as president, extends rule into 3rd decade
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
China's 1st domestically made passenger plane completes maiden commercial flight
Sell every Stock except ONE (Ad)
In Nigeria’s hard-hit north, families seek justice as armed groups seek control
Biden and McCarthy reach a final deal to avoid US default and now must sell it to Congress
Free A.I. Trade Alerts. Up to 15 opportunities a day. (Ad)
EgyptAir flight from Cairo blows tire during landing in Saudi Arabia
Russia launched 'largest drone attack' on Ukrainian capital before Kyiv Day; 1 killed
3 Free Stock Picks per Day (Ad)
'Succession' fans brace for series finale of Emmy-winning hit drama
Turkey's Erdogan wins another term as president, extends rule into 3rd decade
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
China's 1st domestically made passenger plane completes maiden commercial flight
Sell every Stock except ONE (Ad)
In Nigeria’s hard-hit north, families seek justice as armed groups seek control
Biden and McCarthy reach a final deal to avoid US default and now must sell it to Congress
Free A.I. Trade Alerts. Up to 15 opportunities a day. (Ad)
EgyptAir flight from Cairo blows tire during landing in Saudi Arabia
Russia launched 'largest drone attack' on Ukrainian capital before Kyiv Day; 1 killed
3 Free Stock Picks per Day (Ad)
'Succession' fans brace for series finale of Emmy-winning hit drama
Turkey's Erdogan wins another term as president, extends rule into 3rd decade
NASDAQ:SAGE

Sage Therapeutics (SAGE) Competitors

$50.23
+1.08 (+2.20%)
(As of 05/26/2023 ET)
Compare
Today's Range
$48.89
▼
$50.44
50-Day Range
$40.65
▼
$53.38
52-Week Range
$30.67
▼
$54.86
Volume
338,483 shs
Average Volume
556,975 shs
Market Capitalization
$3.00 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$51.54
ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability

SAGE vs. AXSM, IMGN, BHC, RETA, ZLAB, FOLD, GLPG, MRVI, SDGR, and RVNC

Should you be buying Sage Therapeutics stock or one of its competitors? The main competitors of Sage Therapeutics include Axsome Therapeutics (AXSM), ImmunoGen (IMGN), Bausch Health Companies (BHC), Reata Pharmaceuticals (RETA), Zai Lab (ZLAB), Amicus Therapeutics (FOLD), Galapagos (GLPG), Maravai LifeSciences (MRVI), Schrödinger (SDGR), and Revance Therapeutics (RVNC). These companies are all part of the "pharmaceutical preparations" industry.

Sage Therapeutics vs.

Axsome Therapeutics (NASDAQ:AXSM) and Sage Therapeutics (NASDAQ:SAGE) are both mid-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their institutional ownership, community ranking, profitability, earnings, valuation, risk, media sentiment, dividends and analyst recommendations.

Axsome Therapeutics has higher revenue and earnings than Sage Therapeutics. Axsome Therapeutics is trading at a lower price-to-earnings ratio than Sage Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Axsome Therapeutics$50.04 million60.78-$187.13 million-$3.80-18.37
Sage Therapeutics$7.69 million390.34-$532.78 million-$9.37-5.36

Sage Therapeutics received 231 more outperform votes than Axsome Therapeutics when rated by MarketBeat users. Likewise, 71.73% of users gave Sage Therapeutics an outperform vote while only 67.60% of users gave Axsome Therapeutics an outperform vote.

CompanyUnderperformOutperform
Axsome TherapeuticsOutperform Votes
388
67.60%
Underperform Votes
186
32.40%
Sage TherapeuticsOutperform Votes
619
71.73%
Underperform Votes
244
28.27%

Axsome Therapeutics currently has a consensus price target of $105.57, suggesting a potential upside of 51.25%. Sage Therapeutics has a consensus price target of $51.54, suggesting a potential upside of 2.60%. Given Axsome Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Axsome Therapeutics is more favorable than Sage Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Axsome Therapeutics
1 Sell rating(s)
2 Hold rating(s)
10 Buy rating(s)
0 Strong Buy rating(s)
2.69
Sage Therapeutics
0 Sell rating(s)
8 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.27

59.7% of Axsome Therapeutics shares are held by institutional investors. Comparatively, 85.6% of Sage Therapeutics shares are held by institutional investors. 24.5% of Axsome Therapeutics shares are held by insiders. Comparatively, 4.8% of Sage Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

In the previous week, Axsome Therapeutics had 2 more articles in the media than Sage Therapeutics. MarketBeat recorded 12 mentions for Axsome Therapeutics and 10 mentions for Sage Therapeutics. Sage Therapeutics' average media sentiment score of 0.48 beat Axsome Therapeutics' score of 0.18 indicating that Sage Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Axsome Therapeutics
2 Very Positive mention(s)
1 Positive mention(s)
4 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral
Sage Therapeutics
1 Very Positive mention(s)
2 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Axsome Therapeutics has a net margin of -109.75% compared to Sage Therapeutics' net margin of -5,932.09%. Sage Therapeutics' return on equity of -42.32% beat Axsome Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Axsome Therapeutics -109.75% -152.04% -48.29%
Sage Therapeutics -5,932.09% -42.32% -39.37%

Axsome Therapeutics has a beta of 1.9, indicating that its stock price is 90% more volatile than the S&P 500. Comparatively, Sage Therapeutics has a beta of 1.16, indicating that its stock price is 16% more volatile than the S&P 500.

Summary

Axsome Therapeutics beats Sage Therapeutics on 10 of the 18 factors compared between the two stocks.


New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SAGE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

SAGE vs. The Competition

Export to Excel
MetricSage TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$3.00B$5.81B$4.57B$6.18B
Dividend YieldN/A2.72%2.32%6.15%
P/E Ratio-5.367.54100.8013.62
Price / Sales390.34319.413,697.2086.33
Price / CashN/A20.5598.00107.27
Price / Book2.655.095.047.13
Net Income-$532.78M$188.69M$118.58M$192.91M
7 Day Performance-5.28%-2.49%1.09%0.20%
1 Month Performance2.82%1.52%1.28%1.33%
1 Year Performance55.80%17.02%19.54%-0.24%

Sage Therapeutics Competitors List

Export to Excel
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
AXSM
Axsome Therapeutics
2.3166 of 5 stars		$71.82
-3.8%		$105.57
+47.0%		+163.8%$3.13B$50.04M-18.90108Analyst Revision
IMGN
ImmunoGen
1.9674 of 5 stars		$13.98
-3.8%		$13.71
-1.9%		+264.6%$3.16B$108.78M-14.87106Short Interest ↓
BHC
Bausch Health Companies
1.9582 of 5 stars		$8.41
-4.4%		$8.67
+3.1%		-17.5%$3.04B$8.12B-8.5819,900Gap Down
RETA
Reata Pharmaceuticals
2.2017 of 5 stars		$79.22
-0.3%		$99.89
+26.1%		+211.5%$2.97B$2.22M0.00346
ZLAB
Zai Lab
2.1155 of 5 stars		$33.73
-1.5%		$94.33
+179.7%		+6.9%$3.30B$215.04M-7.882,036
FOLD
Amicus Therapeutics
2.0087 of 5 stars		$11.75
-0.4%		$15.20
+29.4%		+39.7%$3.32B$329.23M-16.79496Analyst Revision
GLPG
Galapagos
0.924 of 5 stars		$44.46
-0.1%		$45.37
+2.0%		-24.9%$2.93B$547.80M-15.991,338
MRVI
Maravai LifeSciences
2.6182 of 5 stars		$13.64
+0.3%		$20.20
+48.1%		-61.9%$3.42B$883M11.86470Analyst Report
Short Interest ↑
Gap Down
SDGR
Schrödinger
2.0315 of 5 stars		$38.52
-1.1%		$50.00
+29.8%		+35.8%$2.74B$180.96M296.33664Insider Selling
High Trading Volume
RVNC
Revance Therapeutics
2.0641 of 5 stars		$31.47
-3.2%		$42.36
+34.6%		+117.6%$2.73B$156.64M-6.83495

Related Companies and Tools

Related Companies:
Top 10 Stock Comparisons
This page (NASDAQ:SAGE) was last updated on 5/28/2023 by MarketBeat.com Staff

My Account -